Evidence map›Paper›PMID 39687264›Full record

ArticleRevista panamericana de salud publica = Pan American journal of public health2024

[High-quality Follow-up Measles and Rubella vaccination Campaign in Mexico, 2021Campanha de vacinação de seguimento de alta qualidade contra sarampo e rubéola no México, 2021].

José Luis Díaz-Ortega, Regina Durón-Andino, Cesar Omar Zuñiga-Ocampo, José Gerardo Rios-Castillo, Eva Román-Castro, Luis Humberto González-Ramírez, José Manasés Aguilar-Villaseñor, María Guadalupe Jacobo-Ramírez

Abstract readCase ReportsEnglish Abstract
In one paragraph

Article in Revista panamericana de salud publica = Pan American journal of public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

José Luis Díaz-OrtegaCentro Nacional para la Salud de la Infancia y la Adolescencia Ciudad de México México Centro Nacional para la Salud de la Infancia y la Adolescencia, Ciudad de México, México.
Regina Durón-AndinoOrganización Panamericana de la Salud Ciudad de México México Organización Panamericana de la Salud, Ciudad de México, México.
Cesar Omar Zuñiga-OcampoCentro Nacional para la Salud de la Infancia y la Adolescencia Ciudad de México México Centro Nacional para la Salud de la Infancia y la Adolescencia, Ciudad de México, México.
José Gerardo Rios-CastilloOrganización Panamericana de la Salud Ciudad de México México Organización Panamericana de la Salud, Ciudad de México, México.
Eva Román-CastroCentro Nacional para la Salud de la Infancia y la Adolescencia Ciudad de México México Centro Nacional para la Salud de la Infancia y la Adolescencia, Ciudad de México, México.
Luis Humberto González-RamírezOrganización Panamericana de la Salud Ciudad de México México Organización Panamericana de la Salud, Ciudad de México, México.
José Manasés Aguilar-VillaseñorOrganización Panamericana de la Salud Ciudad de México México Organización Panamericana de la Salud, Ciudad de México, México.
María Guadalupe Jacobo-RamírezOrganización Panamericana de la Salud Ciudad de México México Organización Panamericana de la Salud, Ciudad de México, México.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To describe Mexico's experience of a high-quality follow-up vaccination campaign against measles and rubella in children aged 1 to 4 years, and actions taken to recover the coverage of other biologics during the COVID-19 health emergency. Method: Use of a microplanning tool in the design and implementation of a follow-up campaign to protect 8 604 781 girls and boys aged 1 to 4 years and to complete other vaccination schedules, followed by the implementation of rapid vaccination monitoring. Results: A total of 8 026 184 doses of MR vaccine were administered to children aged 1 to 4 years, with a coverage rate of 93.3%. In addition, 3 058 201 doses of MMR vaccine and 2 361 021 doses of hexavalent vaccine were administered. Rapid vaccination monitoring was carried out 78 times in selected municipalities in the country, where 30% (18 692) of 62 308 children aged 1-4 years contacted were found to be unvaccinated. The reasons for not vaccinating were "not knowing it was necessary" (28.5%), "not having time" (21.2%), "other reasons" (mainly fear of getting sick from COVID-19 in health centers) (12.9%), "believing they had received two doses of MMR vaccine" (9.1%), or "not knowing where to get vaccinated" (8.7%); 19.6% did not respond. Conclusions: The high-quality vaccination campaign was successful, favoring the sustainability of measles, rubella, and polio elimination, as well as the control of other vaccine-preventable diseases, and demonstrating the relevance of microplanning.

Indexed as

campaign, vaccinationCOVID-19hexavalent vaccinemeaslesMexicoparotiditisrubellavaccination coverageVaccines

Identifiers

PMID39687264
PMCPMC11648098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.